Commentary on NOVOS’ Wall Street Journal & Fortune Coverage

In the last two weeks, we at NOVOS have been very fortunate to have been featured in two high quality publications: The Wall Street Journal and Fortune.

I’m very appreciative of the coverage, and I’d like to add additional color to it.

The Wall Street Journal’s NOVOS Coverage

The Wall Street Journal piece covered biological age clocks. The author, Dominique Mosbergen, states, “Researchers of aging think biological age could be a more accurate predictor of lifespan and age-related diseases. They hope to prove that tweaks to diet, exercise and other lifestyle changes or drugs that mimic them could modify biological age.”

She goes on to state, “‘There’s a convergence of a greater understanding of the science of aging and the ability to measure biological age,’ said Dr. Douglas Vaughan, director of Northwestern University’s Potocsnak Longevity Institute. He isn’t affiliated with the testing companies.”

She mentions “testing companies” because NOVOS was not the only company covered in her piece: two others were analyzed.

I had the opportunity to be interviewed by Ms. Mosbergen, and I shared with her the differences between the clocks used in NOVOS Age and the others. These differences didn’t make it into the piece, so I’ll share some of them here.

First, NOVOS Age is the only product that provides three test outputs (the others provide one), because aging isn’t as simple as one single metric: biological pace of aging, biological age, and telomere length. Each of these metrics plays a role in understanding how you’re aging.

I’ve covered these tests in the past, and NOVOS offers a comprehensive comparison, but what I’ll emphasize here is the pace of aging test. We provide the DunedinPACE clock to customers, licensed from Columbia and Duke University researchers. This test is arguably the most accurate and precise of all biological age clocks (ICC > 0.97; no other clocks have demonstrated that they achieve this standard). As of the creation of this article, the other companies haven’t publish their clocks’ accuracy or precision information.

When it comes to biological age clocks, precision is of utmost importance. Think about it: what good would a scale be if each time you stepped on it, it varied by 5% to 10% above or below your weight?

Next, NOVOS’ pace clock has been analyzed in more than 45 scientific studies across more than 20 global scientific labs, and proven itself to be applicable to diverse ethnicities, ages, and responds to lifestyle interventions (the other clocks are black boxes with no academic scrutiny). For example, as published in Nature Aging, the DunedinPACE clock used by NOVOS Age responds favorably to caloric restriction; other clocks, including Horvath, Hannum, Levine, and GrimAge do not. The burden of proof is on others to demonstrate that they, too, respond to well studied longevity interventions.

NOVOS’ clock is a third generation clock, the latest generation of epigenetic biological age clocks.

At NOVOS we had considered building a biological age clock of our own, but ultimately decided to put quality ahead of profits: DunedinPACE is the best biological age clock currently available, and that’s what we are intent to provide to our customers.

Towards the end of the article, Ms. Mosbergen mentions NOVOS’ formulations. She accurately highlights how NOVOS stands out from others by stating “[NOVOS] tested its supplements in a study of about 40 people and is planning more clinical trials with larger groups of people.” (Not mentioned in the article, this found 73% of participants slowed their pace of aging, 0% accelerated, with a p-value of 0.001).

However, she proceeds to state, “Kaeberlein, who consults for Novos but said he doesn’t endorse their products.” Many have told me they feel this gives the wrong impression, so let me clarify.

As a principled scientist, Matt Kaeberlein doesn’t endorse supplements. However, as Matt shared with me and Ms. Mosbergen, he does even better than that: he personally takes NOVOS Core every morning in his protein shake. Coming from Matt, that says a lot! Unfortunately, this didn’t make it into the article.

Matt also shared with me and Ms. Mosbergen that he considers NOVOS to be in a class of its own when it comes to scientific process and reputability. It’s understandable that as a journalist Ms. Mosbergen tries to remain neutral, which is why I have provided this additional detail.


The second article was published this week in Fortune Well. The article provides the female perspective on longevity, which we need to hear a whole lot more of!

Specifically, the article features two NOVOS Core and Age customers: Julie Gibson Clark (55, single mom, pace of aging: 0.665) and Amy Hardison (63, pace of aging: 0.73). They are highlighted because they have outranked Bryan Johnson on his own Rejuvenation Olympics leadership board.

“Her biggest health expenditures are a $27-a-month gym membership and an $79-a-month supplement subscription [NOVOS].

So the 55-year-old single mom in Phoenix, Arizona was surprised to learn she ranks at No.2 on the worldwide leaderboard of an online competitive longevity game, the Rejuvenation Olympics, which tracks and ranks about 4,000 participants’ pace of what’s sometimes called ‘biological” aging.'”


While Johnson spends $2 million per year to slow his aging, Julie and Amy spend $79 per month on NOVOS Core.

Rick Chiovarelli (70), a NOVOS customer, also appears on the leaderboard, just one place behind Bryan, and two additional NOVOS customers are expected to make the top ten placement once the list is refreshed. These people did not make it into the article. All of these successes have been based off of daily ingestion of either NOVOS Core alone, or NOVOS Core plus Boost together, and no other lifestyle interventions.

No other company in the consumer longevity space can make a claim that compares to this, and we at NOVOS are very proud of this fact!

Closing Thoughts

At NOVOS, we have built the most solid consumer longevity biotech company–the first of its kind–that leverages the latest scientific advancements, its own in-house R&D team, and third party longevity researchers at labs across the world.

While we will continue to inspire others to follow suit, there is and will always be only one NOVOS!